1. Generics Bulletin

US Supreme Court Refuses ‘Blocking-Patent’ Review

Acorda has been refused its certiorari request

 
• By Dave Wallace

Acorda has been denied its request for the US Supreme Court to review a ruling that revolved around the ‘blocking-patent’ doctrine, which has led to invalidity rulings on patents protecting several major brands.

Barrier tape
The case revolved around the ‘blocking-patent’ doctrine • Source: Shutterstock

Litigation revolving around the ‘blocking-patent’ doctrine and involving Acorda Therapeutics along with Mylan, Hikma’s Roxane and Teva will not be reviewed by the US Supreme Court, after it refused the originator’s certiorari petition.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Generics Bulletin

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Discounted Ustekinumab Biosimilars Further Dent J&J’s Q1 Stelara Sales

 
• By Urtė Fultinavičiūtė

With discounts reaching up to 90%, ustekinumab biosimilars have eroded originator Stelara’s sales as expected. In its latest quarterly biosimilar market report, Samsung Bioepis also analyzed the latest regulatory steps to streamline biosimilar development.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.